ALV-100の安全性、忍容性、およびPK/PDを、過体重/肥満のT2D有無の参加者で評価する研究
ALV-100の安全性、忍容性、薬物動態、薬力学を評価する、過体重または肥満(2型糖尿病の有無を問わず)の参加者を対象とした第1b相、無作為化、二重盲検、プラセボ対照、用量漸増試験
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Florida
-
Miami、Florida、アメリカ、33172
- Clinical Pharmacology of Miami
-
-
Ohio
-
Columbus、Ohio、アメリカ、43212
- Ohio Clinical Trials
-
-
Texas
-
San Antonio、Texas、アメリカ、78240
- Endeavor Clinical Trials
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
For Part A and B
- Adult male and female participants, aged 18 to 65 years, inclusive, at the time of signing the informed consent form
- Body mass index between 27.0 to 39.9 kg/m2 at Screening, both inclusive; overweight should be due to excess adipose tissue, as judged by the Investigator.
- Have a stable body weight (< 5.0 kg/11 lbs self-reported change) within 90 days prior to Screening
- Females must be surgically sterile (by means of bilateral salpingectomy, hysterectomy or bilateral oophorectomy) or be post-menopausal (defined as spontaneous cessation of menses for at least 1 year prior to Screening). Females who are post-menopausal and < 55 years must have a follicle-stimulating hormone level > 40 IU/L at Screening.
- Males with female partners of child-bearing potential must be willing to practice abstinence or must agree to use condom as contraception throughout the duration of the study. This criterion may be waived for male participants who have had a documented successful vasectomy > 6 months before signing the ICF.
For Part B only
- Diagnosis of Type 2 Diabetes for at least 180 days prior to Screening.
- Glycemic control managed by diet and exercise alone or by stable treatment with metformin and/or sodium-glucose cotransporter 2 inhibitors (SGLT-2i), with no dose changes within 3 months prior to Screening.
- Hemoglobin A1c (HbA1c) between 6.5 % and 9.0% (equivalent to 48-75 mmol/mol), both inclusive, at Screening.
Exclusion Criteria:
For Part A and B
- History or presence of any clinically relevant respiratory, metabolic (including dyslipidemia, however screening total cholesterol below or equal to 302 mg/dL (7.8 mmol/L) and/or screening triglyceride below or equal to 500 mg/dL (5.65 mmol/L) is accepted), renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with type 2 diabetes in Part B) at the discretion of the Investigator.
- Participants with a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 or a personal history of nonfamilial medullary thyroid carcinoma.
- Current or history of chronic or acute pancreatitis.
- Obesity caused by known endocrinologic disorders (e.g., Cushing syndrome) or monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndrome).
- History of major depressive disorder or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or anxiety disorder).
- Lifetime history of a suicide attempt or of any suicidal behavior by endorsement of (answered yes to) any of the items in the suicidal behavior section on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening.
- Systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at Screening.
- History of or current cardiovascular disease, including but not limited to stable and unstable angina, myocardial infarction, congestive heart failure, transient ischemic attack, stroke, clinically significant arrhythmias and conduction disorders or venous thromboembolism.
Part A only
• History or clinical evidence of Type 1 or Type 2 diabetes mellitus, including HbA1c ≥ 6.5% and/or a fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) at Screening (female participants with a history of gestational diabetes are allowed).
Part B only
- Fasting plasma glucose (FPG) > 270 mg/dL (15.0 mmol/L) at Screening.
- Proliferative retinopathy or maculopathy as judged by the investigator based on a recent (within1.5 years from Screening) ophthalmologic examination.
- Severe neuropathy as judged by the investigator.
- Advanced nephropathy (defined as albuminuria ≥ 300 mg/g).
- History of severe hypoglycemia or hypoglycemic unawareness as judged by the investigator.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part A - Cohort 1 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
プラセボコンパレーター:Part A - Cohort 1 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
実験的:Part A - Cohort 2 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
プラセボコンパレーター:Part A - Cohort 2 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
実験的:Part A - Cohort 3 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
プラセボコンパレーター:Part A - Cohort 3 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
実験的:Part A - Cohort 4 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
プラセボコンパレーター:Part A - Cohort 4 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
実験的:Part B - T2D Cohort (ALV-100)
Participants with overweight or obesity with type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
プラセボコンパレーター:Part B - T2D Cohort (Placebo)
Participants with overweight or obesity with type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety and tolerability
時間枠:From First Dose to Week 52
|
Incidence of treatment emergent adverse events (TEAEs) |
From First Dose to Week 52
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pharmacokinetics (PK) of intact ALV-100 and total ALV-100 - Cmax, MD
時間枠:From First Dose to Week 52
|
Maximum observed serum concentration after multiple doses (MD) (Cmax, MD) |
From First Dose to Week 52
|
|
Pharmacokinetics (PK) of intact ALV-100 and total ALV-100 - AUC(0-τ), MD
時間枠:From First Dose to Week 52
|
Area under the serum concentration-time curve from time zero to τ, where τ is the dosing interval, (AUC(0-τ), MD) |
From First Dose to Week 52
|
|
Pharmacodynamic (PD) impact on body weight
時間枠:Baseline, Week 32 and Week 52
|
Change from baseline in body weight |
Baseline, Week 32 and Week 52
|
|
Pharmacodynamic (PD) impact on body weight percentage
時間枠:Baseline, Week 32 and Week 52
|
Change from baseline in body weight percentage |
Baseline, Week 32 and Week 52
|
|
Immunogenicity
時間枠:From Baseline to Week 52
|
Incidence of Anti-ALV-100 drug antibodies, including assessments of cross-reactivity and neutralizing antibodies. |
From Baseline to Week 52
|
|
Relationship between ALV-100 serum concentration and QTc interval changes (Part A Only)
時間枠:From First Dose to Week 52
|
Measurement of change in individual specific heart rate corrected QT interval (QTcI) and Fridericia heart rate corrected QT interval (QTcF) on 12-lead ECG. |
From First Dose to Week 52
|
|
Paracetamol (acetaminophen) absorption test (PAT) (Part A Only)
時間枠:From First Dose to Week 52
|
Measurement of acetaminophen PK parameters to evaluate the effect of ALV-100 on the gastric emptying rate. |
From First Dose to Week 52
|
|
Pharmacodynamic (PD) impact of ALV-100 on antidiabetic medication (Part B Only)
時間枠:From Baseline to Week 32
|
Change in use of concomitant glucose-lowering medication |
From Baseline to Week 32
|
|
Pharmacodynamic (PD) impact of ALV-100 on glycemic parameters (Part B Only)
時間枠:Week 32 and Week 52
|
Measuring the number of participants achieving target Hemoglobin A1c values |
Week 32 and Week 52
|
|
Hypoglycemic Safety (Part B Only)
時間枠:From Baseline to Week 52
|
Measured by the incidence of symptomatic hypoglycemia, documented symptomatic hypoglycemia and severe hypoglycemia |
From Baseline to Week 52
|
協力者と研究者
捜査官
- スタディディレクター:Karen Tornøe, MD, PhD、Alveus Therapeutics
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。